##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, DC 20549
 FORM 10-Q
  þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 For the quarterly period ended March 31, 2011
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 For the transition period from  to .
 Commission File No. 1-15803
 AVANIR PHARMACEUTICALS, INC.
  Delaware
(State or other jurisdiction of 
incorporation or organization)
    
    33-0314804
(I.R.S. Employer Identification No.)
 101 Enterprise Suite 300, Aliso Viejo, California
(Address of principal executive offices)
    
    92656
(Zip Code)
 (949) 389-6700
 þ o
 o o
  Large accelerated filer o
    
    Accelerated filer þ
    
    Non-accelerated filer o
(Do not check if a smaller reporting company)
    
    Smaller reporting company o
 o þ




---



##### 



Table of Contents
  
 PagePART I. FINANCIAL INFORMATIONItem 1. Financial StatementsCondensed Consolidated Balance Sheets
    
    
    3Condensed Consolidated Statements of Operations
    
    
    4Condensed Consolidated Statements of Cash Flows
    
    
    5Notes to Condensed Consolidated Financial Statements
    
    
    6Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    22Item 3. Quantitative and Qualitative Disclosures about Market Risk
    
    
    30Item 4. Controls and Procedures
    
    
    31PART II. OTHER INFORMATIONItem 1. Legal Proceedings
    
    
    31Item 1A. Risk Factors
    
    
    31Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    46Item 3. Defaults Upon Senior Securities
    
    
    46Item 4. Removed and Reserved
    
    
    46Item 5. Other Information
    
    
    46Item 6. Exhibits
    
    
    47Signatures
    
    
    48EX-10.1EX-31.1EX-31.2EX-32.1
  2




---



##### Table of Contents



PART I. FINANCIAL INFORMATION
 
 Item 1. FINANCIAL STATEMENTS
 AVANIR PHARMACEUTICALS, INC.
 
 CONDENSED CONSOLIDATED BALANCE SHEETS
 March 31,
    
    
    September 30,2011
    
    
    2010(unaudited)
    
    
    (audited)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    103,047,047
    
    
    $
    38,771,469Trade receivables
    
    
    3,215,758
    
    
    
    Stock subscriptions receivable
    
    
    
    
    
    
    580,910Royalty receivables
    
    
    
    
    
    
    29,471Inventories
    
    
    671,001
    
    
    
    652,628Prepaid expenses
    
    
    1,217,915
    
    
    
    432,705Other current assets
    
    
    326,762
    
    
    
    23,396Current portion of restricted investments in marketable securities
    
    
    467,100
    
    
    
    200,000Total current assets
    
    
    108,945,583
    
    
    
    40,690,579Restricted investments in marketable securities, net of current portion
    
    
    1,634,625
    
    
    
    401,550Property and equipment, net
    
    
    674,436
    
    
    
    449,712Non-current inventories
    
    
    258,182
    
    
    
    228,207Other assets
    
    
    795,978
    
    
    
    371,150TOTAL ASSETS
    
    $
    112,308,804
    
    
    $
    42,141,198LIABILITIES AND STOCKHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    1,327,234
    
    
    $
    2,106,110Accrued expenses and other liabilities
    
    
    1,679,533
    
    
    
    1,070,061Accrued compensation and payroll taxes
    
    
    2,336,075
    
    
    
    2,147,371Deferred product revenues, net
    
    
    2,647,091
    
    
    
    Current portion of deferred royalty revenues
    
    
    2,087,226
    
    
    
    2,399,849Total current liabilities
    
    
    10,077,159
    
    
    
    7,723,391Accrued expenses and other liabilities, net of current portion
    
    
    241,158
    
    
    
    334,269Deferred royalty revenues, net of current portion
    
    
    5,274,870
    
    
    
    6,076,982Total liabilities
    
    
    15,593,187
    
    
    
    14,134,642Commitments and contingenciesStockholders equity:Preferred stock  $0.0001 par value, 10,000,000 shares authorized,
no shares issued
or outstanding as of March 31, 2011 and September 30, 2010
    
    
    
    
    
    
    Common stock  $0.0001 par value, 200,000,000 shares authorized;
121,745,120 and 95,965,572 shares issued and outstanding as of
March 31, 2011 and September 30, 2010
    
    
    12,175
    
    
    
    9,597Common stock subscribed but unissued
    
    
    
    
    
    
    580,910Additional paid-in capital
    
    
    427,965,585
    
    
    
    332,100,685Accumulated deficit
    
    
    (331,262,143
    )
    
    
    (304,684,636
    )Total stockholders equity
    
    
    96,715,617
    
    
    
    28,006,556TOTAL LIABILITIES AND STOCKHOLDERS EQUITY
    
    $
    112,308,804
    
    
    $
    42,141,198
  3




---



##### Table of Contents



AVANIR PHARMACEUTICALS, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
 Three Months Ended March 31,
    
    
    Six Months Ended March 31,2011
    
    
    2010
    
    
    2011
    
    
    2010REVENUES FROM PRODUCT SALESGross product sales
    
    $
    504,966
    
    
    $
    
    
    
    $
    504,966
    
    
    $
    Less: discount and allowances
    
    
    (42,952
    )
    
    
    
    
    
    
    (42,952
    )
    
    
    Net product sales
    
    
    462,014
    
    
    
    
    
    
    
    462,014
    
    
    
    Cost of product sales (1)
    
    
    114,327
    
    
    
    
    
    
    
    114,327
    
    
    
    Product gross margin
    
    
    347,687
    
    
    
    
    
    
    
    347,687
    
    
    
    OTHER REVENUESRevenues from royalties
    
    
    974,489
    
    
    
    994,494
    
    
    
    2,792,976
    
    
    
    2,479,428Total gross margin
    
    
    1,322,176
    
    
    
    994,494
    
    
    
    3,140,663
    
    
    
    2,479,428OPERATING EXPENSESResearch and development
    
    
    2,519,390
    
    
    
    3,815,613
    
    
    
    6,363,179
    
    
    
    7,262,503Selling, general and administrative
    
    
    13,278,773
    
    
    
    3,622,704
    
    
    
    23,372,211
    
    
    
    6,489,182Total operating expenses
    
    
    15,798,163
    
    
    
    7,438,317
    
    
    
    29,735,390
    
    
    
    13,751,685Loss from operations
    
    
    (14,475,987
    )
    
    
    (6,443,823
    )
    
    
    (26,594,727
    )
    
    
    (11,272,257
    )OTHER INCOMEInterest income
    
    
    10,051
    
    
    
    2,357
    
    
    
    17,183
    
    
    
    8,161Other, net
    
    
    348
    
    
    
    1,004
    
    
    
    37
    
    
    
    677Net loss
    
    $
    (14,465,588
    )
    
    $
    (6,440,462
    )
    
    $
    (26,577,507
    )
    
    $
    (11,263,419
    )Basic and diluted net loss per share
    
    $
    (0.12
    )
    
    $
    (0.08
    )
    
    $
    (0.23
    )
    
    $
    (0.14
    )Basic and diluted weighted average
number of common shares
outstanding
    
    
    121,635,339
    
    
    
    83,419,640
    
    
    
    114,943,284
    
    
    
    83,288,078
 
 (1)
    
    Cost of product sales includes a write-down of inventory of
approximately $82,000 as discussed in Note 5.  4




---



##### Table of Contents



AVANIR PHARMACEUTICALS, INC.
 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
 Six Months Ended March 31,2011
    
    
    2010OPERATING ACTIVITIES:Net loss
    
    $
    (26,577,507
    )
    
    $
    (11,263,419
    )Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization
    
    
    177,229
    
    
    
    99,397Share-based compensation expense
    
    
    1,784,816
    
    
    
    1,363,837Changes in operating assets and liabilities:Trade receivables
    
    
    (3,215,758
    )
    
    
    Royalty receivables
    
    
    29,471
    
    
    
    (884,988
    )Inventories
    
    
    (48,348
    )
    
    
    Prepaid expenses and other assets
    
    
    (1,513,404
    )
    
    
    143,702Accounts payable
    
    
    (671,544
    )
    
    
    644,208Accrued expenses and other liabilities
    
    
    346,361
    
    
    
    326,904Accrued compensation and payroll taxes
    
    
    188,704
    
    
    
    (541,333
    )Deferred product revenues, net
    
    
    2,647,091
    
    
    
    Deferred royalty revenues
    
    
    (1,114,735
    )
    
    
    (1,076,177
    )Net cash used in operating activities
    
    
    (27,967,624
    )
    
    
    (11,187,869
    )INVESTING ACTIVITIES:Purchase of investments in securities
    
    
    (1,500,175
    )
    
    
    Proceeds from sales and maturities of investments in securities
    
    
    
    
    
    
    66,906Purchase of property and equipment
    
    
    (339,285
    )
    
    
    (48,590
    )Net cash (used in) provided by investing activities
    
    
    (1,839,460
    )
    
    
    18,316FINANCING ACTIVITIES:Proceeds from issuances of common stock, net of commissions
and offering costs
    
    
    87,739,859
    
    
    
    183,044Proceeds from exercise of stock options and warrants
    
    
    5,767,558
    
    
    
    2,994Collection of stock subscriptions receivable
    
    
    580,910
    
    
    
    Shares surrendered to pay for tax withholding
    
    
    (5,665
    )
    
    
    (197,690
    )Net cash provided by (used in) financing activities
    
    
    94,082,662
    
    
    
    (11,652
    )Net increase (decrease) in cash and cash equivalents
    
    
    64,275,578
    
    
    
    (11,181,205
    )Cash and cash equivalents at beginning of period
    
    
    38,771,469
    
    
    
    31,486,012Cash and cash equivalents at end of period
    
    $
    103,047,047
    
    
    $
    20,304,807SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:Income taxes paid
    
    $
    3,200
    
    
    $
    3,200SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND
FINANCING ACTIVITIES:Purchase of property and equipment in accounts payable and accrued
expenses and other liabilities
    
    $
    193,290
    
    
    $
    
  5




---



##### Table of Contents



AVANIR PHARMACEUTICALS, INC.
 
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
 1. BASIS OF PRESENTATION
 Avanir Avanir
   2. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 Description of Business
 Avanir ®
   ®
  6




---



##### Table of Contents



Avanir
 Significant Accounting Policies
  Concentration of Credit Risk and Sources of Supply
    Fair value of financial instruments
  Revenue recognition
  7




---



##### Table of Contents



Product Sales  NUEDEXTA.
   Product Sales  Active Pharmaceutical Ingredient docosanol (docosanol).
 8




---



##### Table of Contents



Multiple Element Arrangements.
  License Arrangements.
   Royalty Arrangements.
  9




---



##### Table of Contents



®
 Cost of product revenues
  Recognition of Expenses in Outsourced Contracts
  Share-Based Compensation
    10




---



##### Table of Contents



For the three months ended
    
    
    For the six months endedMarch 31,
    
    
    March 31,2011
    
    
    2010
    
    
    2011
    
    
    2010Share-based compensation classified as:Selling, general and administrative
expense
    
    $
    798,723
    
    
    $
    518,696
    
    
    $
    1,485,633
    
    
    $
    1,035,608Research and development expense
    
    
    152,485
    
    
    
    146,069
    
    
    
    299,183
    
    
    
    328,229Total
    
    $
    951,208
    
    
    $
    664,765
    
    
    $
    1,784,816
    
    
    $
    1,363,837
 For the three months ended
    
    
    For the six months endedMarch 31,
    
    
    March 31,2011
    
    
    2010
    
    
    2011
    
    
    2010Share-based compensation expense from:Stock options
    
    $
    622,724
    
    
    $
    336,283
    
    
    $
    1,114,077
    
    
    $
    575,233Restricted stock units
    
    
    328,484
    
    
    
    328,482
    
    
    
    670,739
    
    
    
    788,604Total
    
    $
    951,208
    
    
    $
    664,765
    
    
    $
    1,784,816
    
    
    $
    1,363,837
  Income Taxes
       11




---



##### Table of Contents



Recent Authoritative Guidance
 Proposed Amendments to Current Accounting Standards. Revenue from Contracts with Customers Revenue Recognition
 Fees Paid to the Federal Government by Pharmaceutical Manufacturers.
 Milestone Method of Revenue Recognition.
 Multiple-Deliverable Revenue Arrangements.
 12




---



##### Table of Contents



3.
FAIR VALUE MEASUREMENTS
  
    
    Level 1-Quoted prices in active markets for identical assets and liabilities.
    
    Level 2-Inputs other than Level 1 that are observable, either directly or
indirectly, such as quoted prices for similar assets and liabilities, quoted
prices in the markets that are not active, or other inputs that are
observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
    
    Level 3-Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the assets or
liabilities.
  4. RESTRICTED INVESTMENTS IN MARKETABLE SECURITIES
    5. INVENTORIES
  13




---



##### Table of Contents



March 31,
    
    
    September 30,2011
    
    
    2010(audited)Raw materials
    
    $
    718,426
    
    
    $
    554,465Work in progress
    
    
    
    
    
    
    326,370Finished goods
    
    
    196,547
    
    
    
    Inventories subject to return
    
    
    14,210
    
    
    
    Total inventory, net
    
    
    929,183
    
    
    
    880,835Less: current portion
    
    
    (671,001
    )
    
    
    (652,628
    )Non-current portion
    
    $
    258,182
    
    
    $
    228,207
  6. ACCRUED EXPENSES AND OTHER LIABILITIES
  March 31,
    
    
    September 30,2011
    
    
    2010(audited)Accrued royalties, rebates, chargebacks and distribution fees
    
    $
    156,303
    
    
    $
    Accrued research and development expenses
    
    
    437,713
    
    
    
    221,956Accrued selling, general and administrative expenses
    
    
    675,910
    
    
    
    537,347Deferred rent
    
    
    4,049
    
    
    
    12,148Other liabilities
    
    
    170,000
    
    
    
    Lease restructuring liability (1)
    
    
    476,716
    
    
    
    632,879Total accrued expenses and other liabilities
    
    
    1,920,691
    
    
    
    1,404,330Less: Current portion
    
    
    (1,679,533
    )
    
    
    (1,070,061
    )Non-current total accrued expenses and other liabilities
    
    $
    241,158
    
    
    $
    334,269
 
 (1)
    
    In fiscal 2006, the Company relocated all operations other than research and development
from San Diego, California to Aliso Viejo, California. In fiscal 2007, the Company subleased
a total of approximately 49,000 square feet of laboratory and office space in San Diego and
relocated remaining personnel and clinical trial support functions to the Companys offices
in Aliso Viejo, California. Restructuring expenses included recognition of the estimated
loss due to the exit of the Companys leases of approximately $2.1 million. No further costs
were incurred related to these restructuring events in fiscal 2008. In April 2009, the
Company entered into a sublease for office space in San Diego, California. Sublease rental
payments commenced in September 2009 pursuant to this sublease. 14




---



##### Table of Contents



Balance atBalance at
    
    
    
    
    
    
    March 31,September 30, 2010
    
    
    Payments/ Reductions
    
    
    2011(audited)Accrued RestructuringTotal lease restructuring liability
    
    $
    632,879
    
    
    $
    (156,163
    )
    
    $
    476,716Less current portion
    
    
    (298,610
    )
    
    
    
    
    
    
    (285,558
    )Non-current portion
    
    $
    334,269
    
    
    
    
    
    
    $
    191,158
 7. NET DEFERRED REVENUES
 ®
 NUEDEXTAProduct
    
    
    Drug RoyaltyShipments, Net
    
    
    USA Agreement
    
    
    TotalNet deferred revenues as of October 1, 2010
    
    $
    
    
    
    $
    8,476,831
    
    
    $
    8,476,831Changes during the period:Shipments, net
    
    
    3,121,615
    
    
    
    
    
    
    
    3,121,615Recognized as revenues during the period (1)
    
    
    (474,524
    )
    
    
    (1,114,735
    )
    
    
    (1,589,259
    )Net deferred revenues as of March 31, 2011
    
    $
    2,647,091
    
    
    $
    7,362,096
    
    
    $
    10,009,187Classified and reported as:Current portion of deferred revenues
    
    $
    2,647,091
    
    
    $
    2,087,226
    
    
    $
    4,734,317Deferred revenues, net of current portion
    
    
    
    
    
    
    5,274,870
    
    
    
    5,274,870Total net deferred revenues
    
    $
    2,647,091
    
    
    $
    7,362,096
    
    
    $
    10,009,187
 
 (1)
    
    The amount that ultimately will be recognized as net product sales may be different due to
other discounts and allowances, including, but not limited to, wholesaler fees based on
wholesaler shipments, rebates, chargebacks and co-pay assistance. NUEDEXTA Product
 Drug Royalty Agreement
  15




---



##### Table of Contents



8. COMPUTATION OF NET LOSS PER COMMON SHARE
   2011
    
    
    2010Stock options
    
    
    7,405,242
    
    
    
    5,882,458Stock warrants
    
    
    8,505,170
    
    
    
    12,240,437Restricted stock units (1)
    
    
    1,779,410
    
    
    
    2,382,857
 
 (1)
    
    Includes 1,320,981 and 981,228 shares of restricted stock at March 31, 2011 and 2010,
respectively, awarded to directors that have vested but are still restricted until the
directors resign. 9. STOCKHOLDERS EQUITY
    16




---



##### Table of Contents



10. EMPLOYEE EQUITY INCENTIVE PLANS
   Stock Options
 17




---



##### Table of Contents



Weighted AverageWeighted Average
    
    
    Remaining
    
    
    AggregateNumber
    
    
    Exercise Price per
    
    
    Contractual Term
    
    
    Intrinsicof Shares
    
    
    Share
    
    
    (In Years)
    
    
    ValueOutstanding October 1, 2010
    
    
    6,364,265
    
    
    $
    1.69Granted
    
    
    1,626,075
    
    
    $
    4.08Exercised
    
    
    (558,983
    )
    
    $
    0.76Forfeited
    
    
    (26,115
    )
    
    $
    3.97Outstanding March 31, 2011
    
    
    7,405,242
    
    
    $
    2.28
    
    
    
    8.2
    
    
    $
    15,545,417Vested and expected to vest in the future,
March 31, 2011 (1)
    
    
    6,917,254
    
    
    $
    2.26
    
    
    
    8.1
    
    
    $
    14,790,371Exercisable, March 31, 2011
    
    
    2,361,812
    
    
    $
    2.38
    
    
    
    7.2
    
    
    $
    6,127,242
 
 (1)
    
    Vested and expected to vest consists of exercisable options as of March 31, 2011 and
options expected to vest as of March 31, 2011, calculated based on estimated forfeiture rates.    Expected volatility
    
    
    104%  108
    %Weighted-average volatility
    
    
    108
    %Expected term in years
    
    
    5.8Risk-fee interest rate (zero coupon U.S. Treasury Note)
    
    
    1.5%  2.5
    %Expected dividend yield
    
    
    0
    %
 18




---



##### Table of Contents



Options Outstanding
    
    
    Options ExercisableWeightedAverage
    
    
    Weighted
    
    
    
    
    
    
    WeightedRemaining
    
    
    Average
    
    
    
    
    
    
    AverageNumber
    
    
    Contractual
    
    
    Exercise
    
    
    Number
    
    
    ExerciseRange of Exercise Prices
    
    Outstanding
    
    
    Life in Years
    
    
    Price
    
    
    Exercisable
    
    
    Price$0.47- $0.79
    
    
    1,236,909
    
    
    
    7.7
    
    
    $
    0.53
    
    
    
    527,839
    
    
    $
    0.53$0.88
    
    
    1,843,030
    
    
    
    7.3
    
    
    $
    0.88
    
    
    
    815,924
    
    
    $
    0.88$1.20- $1.74
    
    
    1,641,460
    
    
    
    8.4
    
    
    $
    1.70
    
    
    
    564,768
    
    
    $
    1.63$1.80- $4.18
    
    
    2,379,156
    
    
    
    9.4
    
    
    $
    3.56
    
    
    
    148,594
    
    
    $
    2.33$4.60- $19.38
    
    
    304,687
    
    
    
    4.3
    
    
    $
    11.00
    
    
    
    304,687
    
    
    $
    11.007,405,242
    
    
    
    8.2
    
    
    $
    2.28
    
    
    
    2,361,812
    
    
    $
    2.38
 Restricted stock units (RSU).
  Weighted AverageGrant DateNumber of Shares
    
    
    Fair ValueUnvested, October 1, 2010
    
    
    521,203
    
    
    $
    3.46Granted
    
    
    351,813
    
    
    $
    4.12Vested
    
    
    (414,656
    )
    
    $
    1.78Unvested, March 31, 2011
    
    
    458,360
    
    
    $
    5.48
   (Performance RSUs)
  19




---



##### Table of Contents



11. COMMITMENTS AND CONTINGENCIES
 Center for Neurologic Study (CNS) 
   Lease Commitment
 Legal Contingencies 
 20




---



##### Table of Contents



Guarantees and Indemnities 
  12. SEGMENT INFORMATION
     13. SUBSEQUENT EVENTS
   21




---



##### Table of Contents



Item 2.
 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
  EXECUTIVE OVERVIEW
 Avanir ®
   ®
 NUEDEXTA for the Treatment of PBA
    22




---



##### Table of Contents



AVP-923 for the Potential Treatment of Neuropathic Pain
 AVP-923 for the treatment of MS-related pain
      AVP-923 for the treatment of diabetic neuropathic pain
  Avanir
 23




---



##### Table of Contents



Docosanol 10% Cream  Cold Sore Treatment
 ®
   Xenerex Human Antibody Technology  Anthrax/Other Infectious Diseases
   General Information
 info@avanir.com www.avanir.com. www.sec.gov
 24




---



##### Table of Contents



CRITICAL ACCOUNTING POLICIES AND ESTIMATES
   RESULTS OF OPERATIONS
 COMPARISON OF THREE MONTHS ENDED MARCH 31, 2011 AND 2010
 Revenues
 Three months endedMarch 31,2011
    
    
    2010
    
    
    $ ChangeREVENUESNet product sales
    
    $
    462,014
    
    
    $
    
    
    
    $
    462,014Revenue from royalties
    
    
    974,489
    
    
    
    994,494
    
    
    
    (20,005
    )Total revnues
    
    $
    1,436,503
    
    
    $
    994,494
    
    
    $
    442,009
   Cost of Product Sales
  25




---



##### Table of Contents



Operating Expenses
 Three months endedMarch 31,2011
    
    
    2010
    
    
    $ ChangeOPERATING EXPENSESResearch and development
    
    $
    2,519,390
    
    
    $
    3,815,613
    
    
    $
    (1,296,223
    )Selling, general and administrative
    
    
    13,278,773
    
    
    
    3,622,704
    
    
    
    9,656,069Total operating expenses
    
    $
    15,798,163
    
    
    $
    7,438,317
    
    
    $
    8,359,846
 Research and Development Expenses
  Selling, General and Administrative Expenses
  Share-Based Compensation
  Other Income
  Net Loss
  26




---



##### Table of Contents



COMPARISON OF SIX MONTHS ENDED MARCH 31, 2011 AND 2010
 Revenues
 Six months endedMarch 31,2011
    
    
    2010
    
    
    $ ChangeREVENUESNet product sales
    
    $
    462,014
    
    
    $
    
    
    
    $
    462,014Revenue from royalties
    
    
    2,792,976
    
    
    
    2,479,428
    
    
    
    313,548Total revnues
    
    $
    3,254,990
    
    
    $
    2,479,428
    
    
    $
    775,562
  Cost of Product Sales
  Operating Expenses
 Six months endedMarch 31,2011
    
    
    2010
    
    
    $ ChangeOPERATING EXPENSESResearch and development
    
    $
    6,363,179
    
    
    $
    7,262,503
    
    
    $
    (899,324
    )Selling, general and administrative
    
    
    23,372,211
    
    
    
    6,489,182
    
    
    
    16,883,029Total operating expenses
    
    $
    29,735,390
    
    
    $
    13,751,685
    
    
    $
    15,983,705
 Research and Development Expenses
  Selling, General and Administrative Expenses
  27




---



##### Table of Contents



Share-Based Compensation
  Other Income
  Net Loss
  LIQUIDITY AND CAPITAL RESOURCES
   Six months endedMarch 31,2011
    
    

2010
    
    

$ ChangeNet cash used in operating activities
    
    $
    (27,967,624
    )
    
    $
    (11,187,869
    )
   
    $
    (16,779,755
    )Net cash (used in) provided by investing activities
    
    
    (1,839,460
    )
    
    
    18,316
    
   
    
    (1,857,776
    )Net cash provided by (used in) financing activities
    
    
    94,082,662
    
    
    
    (11,652
    )
   
    
    94,094,314Net increase (decrease) in cash and cash equivalents
    
    $
    64,275,578
    
    
    $
    (11,181,205
    )
   
    $
    75,456,783
 Operating activities.
 Investing activities.
 Financing activities.
 28




---



##### Table of Contents



Payments Due by PeriodLess than
    
    
    
    
    
    
    
    
    
    
    More thanTotal
    
    
    1 year
    
    
    1-3 years
    
    
    3-5 years
    
    
    5 yearsOperating lease obligations (1)
    
    $
    6,110,772
    
    
    $
    1,574,907
    
    
    $
    2,426,708
    
    
    $
    1,617,707
    
    
    $
    491,450Purchase obligations (2)
    
    
    2,440,995
    
    
    
    2,440,995
    
    
    
    
    
    
    
    
    
    
    
    Total
    
    $
    8,551,767
    
    
    $
    4,015,902
    
    
    $
    2,426,708
    
    
    $
    1,617,707
    
    
    $
    491,450
 
 (1)
    
    Operating lease obligations are exclusive of payments we expect to receive under subleases.(2)
    
    Purchase obligations consist of the total of trade accounts payable and trade related accrued
expenses at March 31, 2011 which approximates our contractual commitments for goods and
services in the normal course of our business. NUEDEXTA License Milestone Payments.
  29




---



##### Table of Contents



Off-Balance Sheet Arrangements
  Management Outlook
   
 Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
  Interest rate sensitivity
    30




---



##### Table of Contents



Item 4. CONTROLS AND PROCEDURES
 Evaluation of Disclosure Controls and Procedures
   Changes in Internal Controls over Financial Reporting
  
 PART II OTHER INFORMATION
 
 Item 1. LEGAL PROCEEDINGS
  
 Item 1A. RISK FACTORS
  Risks Relating to Our Business
 Our near-term prospects are dependent on NUEDEXTA. If we are unable to successfully
commercialize NUEDEXTA, including successfully maintaining adequate sales, marketing or
distribution capabilities or entering into agreements with third parties to perform some of these
functions, we will not be able to commercialize NUEDEXTA effectively and our ability to generate
significant revenue or achieve profitability will be adversely affected. For example, because
NUEDEXTA contains quinidine, which is a known pro-arrhythmic drug, it is possible that medical
information systems may incorrectly identify NUEDEXTA as contraindicated or otherwise inappropriate
for a patient, even in situations where the risks are substantially less than indicated.
 31




---



##### Table of Contents




    
    recruit and retain adequate numbers of effective sales personnel;
    
    effectively train our sales personnel on NUEDEXTA;
    
    establish and maintain successful sales and marketing and education programs for our
targeted physicians;
    
    manage geographically dispersed sales and marketing operations
    
    obtain adequate reimbursement for NUEDEXTA from a broad range of payors; and
    
    maintain and defend our patent protection and maintain regulatory exclusivity for
NUEDEXTA.
   We have a history of net losses and an accumulated deficit, and we may be unable to generate
sufficient revenue to achieve or maintain profitability in the future.
   32




---



##### Table of Contents



PBA is a new market and estimates vary significantly over the potential market size and our
anticipated revenues over the near and long term.
  Significant safety or drug interaction problems could arise with respect to NUEDEXTA, which
could result in restrictions in NUEDEXTAs label, recalls, withdrawal of NUEDEXTA from the market,
an adverse impact on potential sales of NUEDEXTA, or cause us to alter or terminate current or
future NUEDEXTA clinical development programs, any of which would adversely impact our future
business prospects.
    33




---



##### Table of Contents



We have limited capital resources and may need to raise additional funds to support our
operations.
    We have licensed or sold most of our non-core drug development programs and related assets and
these and other possible future dispositions carry certain risks.
  
    
    diversion of managements attention from normal daily operations of the business;
    
    disputes over earn-outs, working capital adjustments or contingent payment obligations;
    
    insufficient proceeds to offset expenses associated with the transactions; and
    
    the potential loss of key employees following such a transaction.
  34




---



##### Table of Contents



The FDAs safety concerns regarding our prior formulation of NUEDEXTA, known as AVP-923, for
the treatment of PBA extend to other clinical indications that we have been pursuing, including DPN
pain. Due to these concerns, any future development of AVP-923 for other indications, including
central neuropathic pain in patients with MS, is expected to use an alternative lower-dose
quinidine formulation, which may negatively affect efficacy.
  We rely on market research to evaluate the potential commercial acceptance of NUEDEXTA.
  Our issued patents may be challenged and our patent applications may be denied. Either result
would seriously jeopardize our ability to compete in the intended markets for our proposed
products.
  
    
    the claims in any pending patent applications will be allowed or that patent
applications will be granted;
    
    competitors will not develop similar or superior technologies independently, duplicate
our technologies, or design around the patented aspects of our technologies;
    
    our technologies will not infringe on other patents or rights owned by others,
including licenses to other intellectual property that may not be available to us;
    
    any of our issued patents will provide us with significant competitive advantages;
 35




---



##### Table of Contents




    
    challenges will not be instituted against the validity or enforceability of any patent
that we own or have licensed, and, if challenged, that we will be successful in defending
ourselves against these challenges; or
    
    we will be able to secure additional worldwide intellectual property protection for our
NUEDEXTA patent portfolio.
  It is unclear whether we would be eligible for patent-term restoration in the U.S. under
applicable law and we therefore do not know whether our patent-term can be extended.
    NUEDEXTA may face competition from lower cost generic or follow-on products.
  36




---



##### Table of Contents



We may be unable to protect our unpatented proprietary technology and information.
  If we fail to obtain regulatory approval in foreign jurisdictions, we would not be able to
market our products abroad and our revenue prospects would be limited.
  We face challenges recruiting and retaining members of management and other key personnel.
  37




---



##### Table of Contents



Our operations might be interrupted by the occurrence of a natural disaster or other
catastrophic event.
  Future business development activity could disrupt our business and harm our financial
condition.
  
    
    we may have to issue convertible debt or equity securities to complete
business development activities, which would dilute our stockholders
and could adversely affect the market price of our common stock;
    
    business development activity may negatively impact our results of
operations because it may require us to amortize or write down amounts
related to goodwill and other intangible assets, or incur or assume
substantial debt or liabilities, or it may cause adverse tax
consequences, substantial depreciation or deferred compensation
charges;
    
    we may encounter difficulties in assimilating and integrating the
business, products, technologies, personnel or operations of companies
that we acquire;
    
    certain business development activities may impact our relationship
with existing or potential partners who are competitive with the
acquired business, products or technologies;
    
    business development activities may require significant capital
infusions and the acquired businesses, products or technologies may
not generate sufficient value to justify acquisition costs;
    
    business development activity may disrupt our ongoing business, divert
resources, increase our expenses and distract our management;
    
    business development activities may involve the entry into a
geographic or business market in which we have little or no prior
experience; and
    
    key personnel of an acquired company may decide not to work for us.
  38




---



##### Table of Contents



Risks Relating to Our Industry
 The pharmaceutical industry is highly competitive and most of our competitors have larger
operations and have greater resources. As a result, we face significant competitive hurdles.
   If we fail to comply with regulatory requirements, regulatory agencies may take action against
us, which could significantly harm our business.
   We face uncertainty related to healthcare reform, pricing and reimbursement, which could
reduce our revenue.
  39




---



##### Table of Contents




    
    Establish annual, non-deductible fees on any entity that manufactures or imports
certain branded prescription drugs and biologics, beginning in 2011;
    
    Increase minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate
Program;
    
    Extend manufacturers Medicaid rebate liability to covered drugs dispensed to
individuals who are enrolled in Medicaid managed care organizations;
    
    Establish a new Patient-Centered Outcomes Research Institute to oversee, identify
priorities in and conduct comparative clinical effectiveness research;
    
    Require manufacturers to participate in a coverage gap discount program, under which
they must agree to offer 50 percent point-of-sale discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a
condition for the manufacturers outpatient drugs to be covered under Medicare Part D,
beginning in 2011; and
    
    Increase the number of entities eligible for discounts under the Public Health Service
pharmaceutical pricing program, effective January 2010.
    We rely on insurance companies to mitigate our exposure for business activities, including
developing and marketing pharmaceutical products for human use.
  40




---



##### Table of Contents



If we market products in a manner that violates health care fraud and abuse laws, we may be
subject to civil or criminal penalties.
  
    
    the federal healthcare programs Anti-Kickback Law, which prohibits, among other
things, persons from knowingly and willfully soliciting, receiving, offering or paying
remuneration, directly or indirectly, in exchange for or to induce either the referral of
an individual for, or the purchase, order or recommendation of, any good or service for
which payment may be made under federal healthcare programs such as the Medicare and
Medicaid programs;
    
    federal false claims laws which prohibit, among other things, individuals or entities
from knowingly presenting, or causing to be presented, claims for payment from Medicare,
Medicaid, or other third-party payors that are false or fraudulent;
    
    the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA,
which created federal criminal laws that prohibit executing a scheme to defraud any
healthcare benefit program or making false statements relating to healthcare matters; and
    
    state law equivalents of each of the above federal laws, such as anti-kickback and
false claims laws that may apply to items or services reimbursed by any third-party payor,
including commercial insurers.
    41




---



##### Table of Contents



We may incur significant liability if it is determined that we are promoting the off-label use
of drugs.
  There are a number of difficulties and risks associated with clinical trials and our trials
may not yield the expected results.
   
    
    the results from earlier clinical trials may not be predictive of results that will be
obtained from subsequent clinical trials, particularly larger trials;
    
    institutional review boards or regulators, including the FDA, may hold, suspend or
terminate our clinical research or the clinical trials of our product candidates for
various reasons, including noncompliance with regulatory requirements or if, in their
opinion, the participating subjects are being exposed to unacceptable health risks;
    
    subjects may drop out of our clinical trials;
    
    our preclinical studies or clinical trials may produce negative, inconsistent or
inconclusive results, and we may decide, or regulators may require us, to conduct
additional preclinical studies or clinical trials;
    
    trial results derived from top-line data, which is based on a preliminary analysis of
efficacy and safety data related to primary and secondary endpoints, may change following a
more comprehensive review of the complete data set derived from a particular clinical trial
or may change due to FDA requests to analyze the data differently; and
    
    the cost of our clinical trials may be greater than we currently anticipate.
 42




---



##### Table of Contents




    
    delays in our ability to submit an NDA;
    
    the refusal by the FDA to accept for filing any NDA we may submit;
    
    requests for additional studies or data;
    
    delays in obtaining an approval;
    
    the rejection of an application; or
    
    the approval of the drug, but with adverse labeling claims that could adversely affect
the commercial market.
  Risks Related to Reliance on Third Parties
 We depend on third parties to manufacture, package and distribute compounds for our drugs and
drug candidates. The failure of these third parties to perform successfully could harm our
business.
  43




---



##### Table of Contents



Because we depend on clinical research centers and other contractors for clinical testing and
for certain research and development activities, the results of our clinical trials and such
research activities are, to a certain extent, beyond our control.
  We generally do not control the development of compounds licensed to third parties and, as a
result, we may not realize a significant portion of the potential value of any such license
arrangements.
  We expect to rely entirely on third parties for international registration, sales and
marketing efforts.
  Risks Relating to Our Stock
 Our stock price has historically been volatile and we expect that this volatility will
continue for the foreseeable future.
  
    
    comments made by securities analysts, including changes in their recommendations;
    
    short selling activity by certain investors, including any failures to timely settle
short sale transactions;
 44




---



##### Table of Contents




    
    announcements by us of financing transactions and/or future sales of equity or debt
securities;
    
    sales of our common stock by our directors, officers or significant stockholders,
including sales effected pursuant to predetermined trading plans adopted under the
safe-harbor afforded by Rule 10b5-1;
    
    regulatory developments in the U.S. and foreign countries;
    
    lack of volume of stock trading leading to low liquidity; and
    
    market and economic conditions.
    If our internal controls over financial reporting are not considered effective, our business
and stock price could be adversely affected.
   45




---



##### Table of Contents



Because we do not expect to pay dividends in the foreseeable future, you must rely on stock
appreciation for any return on your investment.
  Our corporate governance documents, rights agreement and Delaware law may delay or prevent an
acquisition of us that stockholders may consider favorable, which could decrease the value of our
common stock.
  
 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
  
 Item 3. DEFAULTS UPON SENIOR SECURITIES
  
 Item 4. REMOVED AND RESERVED
 
 Item 5. OTHER INFORMATION
  46




---



##### Table of Contents



Item 6. EXHIBITS
 Exhibits10.1
    
    Summit Office Lease, dated as of
February 1, 2011, by and between Aliso Viejo RP-V1, LLC and
AVANIR Pharmaceuticals, Inc.31.1
    
    Certification of Principal Executive Officer Required Under Rule 13a-14(a) of the Securities
Exchange Act of 1934, as amended.31.2
    
    Certification of Principal Financial Officer Required Under Rule 13a-14(a) of the Securities
Exchange Act of 1934, as amended.32.1
    
    Certification of Principal Executive Officer and Principal Financial Officer Required Under
Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. 1350.
 47




---



##### Table of Contents



SIGNATURES
  Signature
    
    Title
    
    Date/s/ Keith A. Katkin
    
    President and Chief Executive Officer
    
    May 9, 2011Keith A. Katkin
    
    (Principal Executive Officer)/s/ Christine G. Ocampo
    
    Vice President, FinanceChristine G. Ocampo
    
    (Principal Financial Officer and
Principal Accounting Officer)
    
    May 9, 2011
 48